Objective: Evidence has emerged that out-patient management of pulmonary embolism may be an appropriate option in selected patients. This report is based on a safety data on a Pulmonary Embolism Ambulatory Treatment program. Methods: An observational study in acute assessment unit from 2000-2006, of all consecutive patients with confirmed pulmonary embolism (high probability ventilation-perfusion scan or computerized tomography pulmonary angiography), have been evaluated. Exclusion criteria were oxygen saturation less than 92%; systolic blood pressure less than 100 mm Hg; significant cardiopulmonary or renal disease, and a bleeding risk. Patient treated initially with low molecular weight heparin followed by oral anticoagulants when diagnosis was confirmed and were assessed at 3 and 6 months. Results: Sixty-one patients (33 females), median age 55 (range; 16-89 years) were eligible. Patients needed a maximum of 13 appointments. Risk factors included surgery (8.2%), cancer (8.2%), long travel (14.8%), previous thromboembolism (14.8%), hormonal replacement therapy (3.3%) and contraceptive pill (8.2%). No risk factor was identified at 37.7%. The mortality was zero at 6 months. No complications were recorded. Four patients required hospital admission, all within the first week; all were discharged within 24 hours. The median length of stay for patients with uncomplicated pulmonary embolism was 7 days; implementation of the pulmonary embolism ambulatory treatment program saved 427 bed days. Conclusion: The pulmonary embolism ambulatory treatment program was cost-effective and was not associated with serious complications. Further evaluation of these programs could help establish the safety and cost-effectiveness of this approach.
Objective: Evidence has emerged that out-patient management of pulmonary embolism may be an appropriate option in selected patients. This report is based on a safety data on a Pulmonary Embolism Ambulatory Treatment program. Methods: An observational study in acute assessment unit from 2000-2006, of all consecutive patients with confirmed pulmonary embolism (high probability ventilation-perfusion scan or computerized tomography pulmonary angiography), have been evaluated. Exclusion criteria were oxygen saturation less than 92%; systolic blood pressure less than 100 mm Hg; significant cardiopulmonary or renal disease, and a bleeding risk. Patient treated initially with low molecular weight heparin followed by oral anticoagulants when diagnosis was confirmed and were assessed at 3 and 6 months. Results: Sixty-one patients (33 females), median age 55 (range; 16-89 years) were eligible. Patients needed a maximum of 13 appointments. Risk factors included surgery (8.2%), cancer (8.2%), long travel (14.8%), previous thromboembolism (14.8%), hormonal replacement therapy (3.3%) and contraceptive pill (8.2%). No risk factor was identified at 37.7%. The mortality was zero at 6 months. No complications were recorded. Four patients required hospital admission, all within the first week; all were discharged within 24 hours. The median length of stay for patients with uncomplicated pulmonary embolism was 7 days; implementation of the pulmonary embolism ambulatory treatment program saved 427 bed days. Conclusion: The pulmonary embolism ambulatory treatment program was cost-effective and was not associated with serious complications. Further evaluation of these programs could help establish the safety and cost-effectiveness of this approach.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.